Authors
Chris Meulenbroeks, Phylicia Stathi, Marc van de Wetering, Chio Carranza Villarejo, Norman Mack, Benjamin Schwalm, Neal Geisemeyer, Julia Schueler, Anna S Kolodziejczak, Till Milde, Sabine LA Plasschaert, Mariëtte EG Kranendonk, Eelco W Hoving, Paul A Northcott, Martine F Roussel, Stefan M Pfister, Jens Bunt, Marcel Kool
Publication date
2024/6
Journal
Neuro-Oncology
Volume
26
Issue
Suppl 4
Pages
0
Publisher
Oxford University Press
Description
BACKGROUND
Medulloblastoma (MB) is one of the most common malignant pediatric brain tumor types and is subdivided into four major types: WNT, SHH, Group 3 and Group 4. Treatment, including resection, cranio-spinal radiotherapy, and chemotherapy, often leads to undesirable long-term side effects. MB prognosis depends on type, subtype, and genetic alterations, reflecting the high level of heterogeneity observed in these tumors and indicating that specific patient populations with particularly poor prognosis require alternative treatment approaches. Therefore, preclinical models are essential for recapitulating MB heterogeneity and developing subtype-specific treatments.
METHODS
Long-term in vitro MB tumoroid models were developed from patient and PDX tumors and molecularly characterized using DNA methylation and transcriptomic analyses. High-throughput single drug screening (225 compounds …
Scholar articles
C Meulenbroeks, P Stathi, M van de Wetering… - Neuro-Oncology, 2024